NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

KRH-2731: An Orally Bioavailable CXCR4 Antagonist Is a Potent Inhibitor of HIV-1 Infection.

Murakami T, Yoshida A, Tanaka R, Mitsuhashi S, Hirose K, Yanaka M, Yamamoto N, Tanaka Y; Conference on Retroviruses and Opportunistic Infections (11th : 2004 : San Francisco, Calif.).

Program Abstr Conf Retrovir Oppor Infect 11th 2004 San Franc Calif. 2004 Feb 8-11; 11: abstract no. 541.

Univ. of the Ryukyus, Okinawa, Japan

BACKGROUND: Chemokine receptors, CXCR4 and CCR5, which are used as coreceptors by HIV-1, are considered attractive targets for possible intervention of HIV-1 infection. We previously reported KRH-1636 as a duodenally absorbable CXCR4 antagonist and X4 HIV-1 inhibitor. Our continuous efforts to find more effective CXCR4 inhibitors have recently allowed us to identify KRH-2731, an orally bioavailable CXCR4 antagonist.METHODS: Anti-HIV-1 activity of KRH-2731 was assayed with various HIV-1 strains in activated PBMCs. Inhibition of chemokine binding and chemokine receptor-mediated Ca2+ signaling were determined using various chemokine receptor-expressing cells and their ligands. KRH-2731 was orally administered to hu-PBL-SCID mice and tested for its in vivo activity. Pharmacokinetic properties of KRH-2731 were determined in rats and dogs.RESULTS: KRH-2731 efficiently inhibited the replication of all X4 and R5X4 HIV-1 strains tested (EC50 of 1.0 to 4.2 nM), but did not inhibit that of R5 HIV-1 strains in activated PBMC. KRH-2731 specifically inhibited SDF-1alpha binding to CXCR4 and SDF-1-alpha-induced increase in the intracellular Ca2+ concentration of HOS/CXCR4 cells. The binding site of KRH-2731 was located in the second and/or third extracellular loops of CXCR4. KRH-2731 successfully suppressed X4 HIV-1 replication in hu-PBL-SCID mice when administered orally at a dose of 10 mg/kg. When KRH-2731 was administered orally to rats at a dose of 10 mg/kg, its bioavailability was 37%.CONCLUSIONS: KRH-2731 is an orally bioavailable CXCR4 antagonist with a potent and selective anti-X4 HIV-1 activity in both in vitro and in vivo, indicating a desirable additive to an anti-HIV-1 therapy.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Animals
  • Chemokine CXCL12
  • Chemokines, CXC
  • Dogs
  • HIV Infections
  • HIV-1
  • In Vitro
  • KRH 1636
  • Mice
  • Mice, SCID
  • Pyridines
  • Rats
  • Receptors, CCR5
  • Receptors, CXCR4
  • Receptors, Chemokine
  • antagonists & inhibitors
Other ID:
  • GWAIDS0031866
UI: 102271503

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov